Opinion
Video
Reflex Testing for Patients with Suspected Lung Cancer
Key opinion leaders highlight findings from a University of Pennsylvania study demonstrating that implementing reflex next-generation sequencing testing can reduce time-to-treatment from 19 days to 10 days, potentially leading to improved overall patient outcomes and survival rates in non-small cell lung cancer.
EP: 1.Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing
EP: 2.Concurrent NSCLC Biomarker Testing at Diagnosis
EP: 3.NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing
EP: 4.Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer
EP: 5.Biomarker Testing in Early-Stage NSCLC
Now Viewing
EP: 6.Reflex Testing for Patients with Suspected Lung Cancer
EP: 7.Challenges of NSCLC Biomarker Testing in Clinical Practice
EP: 8.Overcoming Barriers to NSCLC Biomarker Testing
EP: 9.Key Takeaways for Concurrent Biomarker Testing in NSCLC
- Please discuss the rationale for conducting liquid-based testing at the time of diagnostic biopsy in patients with suspected advanced NSCLC vs a reflex testing approach. (Thompson JC, et al. JTO Clin Res Rep, 2022)
- What do prospective data demonstrate?
- Please comment on the goal of having test results available upon the first patient interaction.
- Please discuss data surrounding the impact of concurrent liquid and tissue-based testing on the quality of care in advanced NSCLC. (Maity, et al. JCO Oncology Practice, 2023)
- What impact does concurrent testing have on time to diagnosis, the need for repeat tissue biopsy, detection of actionable biomarkers?
- What are some limitations associated with tissue-based testing?
- What do data demonstrate regarding the availability of molecular testing results and overall survival of patients with advanced NSCLC? (Aggarwal, et al. JCO Prec Oncol, 2023)
Related Videos
Related Content
